Accentia Biopharmaceuticals Inc (1310094) SEC Filing 10-Q Quarterly report for the period ending Saturday, December 31, 2011

Accentia Biopharmaceuticals Inc

CIK: 1310094
Document And Entity Information
3 Months Ended
Dec. 31, 2011
Jan. 31, 2012
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Dec. 31, 2011  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2012  
Entity Central Index Key 0001310094  
Current Fiscal Year End Date --09-30  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   76,041,068

View differences made from one quarter to another to evaluate Accentia Biopharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Accentia Biopharmaceuticals Inc.


Assess how Accentia Biopharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Accentia Biopharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2012 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
CIK: 1310094
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-12-052836
Submitted to the SEC: Fri Feb 10 2012 4:58:54 PM EST
Accepted by the SEC: Fri Feb 10 2012
Period: Saturday, December 31, 2011
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink: